Ozsutcu Mustafa, Ayintap Emre, Akkan Julide C U, Koytak Arif, Aras Cengiz
Department of Ophthalmology, Bezmialem Vakif University, Istanbul, Turkey.
Indian J Ophthalmol. 2014 Apr;62(4):407-11. doi: 10.4103/0301-4738.120220.
To evaluate the efficacy of repeated bevacizumab injection in rotational conjunctival flap surgery versus rotational conjunctival flap with adjunctive mitomycin C (MMC) or rotational conjunctival flap alone.
Ninety eyes of 90 patients who underwent primary pterygium surgery with rotational flap were evaluated. Patients were randomly assigned to undergo conjunctival rotational flap alone (Group A) or conjunctival rotational flap with either 0.02% MMC application (Group B) or adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C). Each group consisted of 30 eyes. Recurrence rates at 9 months were evaluated.
There were no statistically significant differences in mean size of the pterygium across the limbus in terms of length (P > 0.5). The recurrence rates at 9 months were 26.6% (n = 8) in Group A, 13.3% (n = 4) in Group B, and 10% (n = 3) in Group C. The recurrence rates in Group B and C were significantly lower than in Group A (P = 0.1806). The recurrence rates were similar in Group B and C (P > 0.05).
Subconjunctival bevacizumab injection may decrease the recurrence rate of primary pterygium surgery with rotational conjunctival flap. Further studies with a larger population and longer follow-up period are needed to supplement this study.
评估在旋转结膜瓣手术中重复注射贝伐单抗与联合丝裂霉素C（MMC）的旋转结膜瓣手术或单纯旋转结膜瓣手术相比的疗效。
对90例行旋转瓣原发性翼状胬肉手术的患者的90只眼进行评估。患者被随机分配接受单纯结膜旋转瓣手术（A组）或结膜旋转瓣联合0.02%MMC应用（B组）或结膜下注射2.5mg/0.1ml贝伐单抗辅助治疗（C组）。每组由30只眼组成。评估9个月时的复发率。
在翼状胬肉横跨角膜缘的平均大小方面，各组在长度上无统计学显著差异（P>0.5）。9个月时的复发率在A组为26.6%（n=8），B组为13.3%（n=4），C组为10%（n=3）。B组和C组的复发率显著低于A组（P=0.1806）。B组和C组的复发率相似（P>0.05）。
结膜下注射贝伐单抗可能降低旋转结膜瓣原发性翼状胬肉手术的复发率。需要进行更大样本量和更长随访期的进一步研究来补充本研究。
